Archived Releases
November 2003
04/11/03
Bioniche Reports First Quarter Fiscal 2004 Results
October 2003
21/10/03
Nebraska Research Studies Confirm Efficacy of E. coli Vaccine
September 2003
15/09/03
Bioniche Reports 2003 Year-End Results
09/09/03
Bioniche Completes Second Tranche of $13.5 Million Financing
August 2003
15/08/03
Preliminary Results of North American Cystistat® Trial Announced
July 2003
14/07/03
Bioniche Pharma Group Receives FDA Approval For Cardiovascular Sterile Injectable
June 2003
17/06/03
Two Research Studies on Canadian E. coli Vaccine Presented at VTEC International Symposium in Edinburgh
06/06/03
Bioniche Announces Private Financing Completion
03/06/03
Bioniche Ranked Among Canada’s Top 100 Fastest Growing Companies
03/06/03
Bioniche Ranked Among Canada’s Top 100 Fastest Growing Companies
02/06/03
Results of Independent European Study on Cystistat®
May 2003
26/05/03
Bioniche Life Sciences Inc. Completes $13.5 Million Financing
23/05/03
Third Quarter Results
22/05/03
Bioniche Reaches Agreement with Fidia Farmaceutici S.p.A.
April 2003
30/04/03
Urology Platform Presented at American Urology Association Annual Meeting
March 2003
18/03/03
Bioniche Life Sciences Announces Additional Bladder Cancer Results
February 2003
17/02/03
Bioniche Posts 40% Consolidated Revenue Increase
January 2003
08/01/03
Bioniche Pharma Receives FDA Approval For Promethazine 10ml
December 2002
13/12/02
Bioniche Receives FDA Approval For Urology Product
October 2002
31/10/02
Bioniche Announces Webcast of Fiscal 2003 First Quarter Results Conference Call
30/10/02
Bioniche Life Sciences Announces First Quarter 2003 Results
30/10/02
Bioniche Launches Amiodarone I.V. Vials in the U.S. with Baxter
17/10/02
Bioniche Receives FDA Approval For Sterile Injectable
September 2002
30/09/02
Bioniche Presents Positive anti-cancer data in leukemia and lymphoma
24/09/02
Bioniche Makes Four Presentations At Prestigious SIU Congress
05/09/02
Bioniche Life Sciences Reports 2002 Year-End Results
03/09/02
Bioniche Defends Patent Infringement Litigation
July 2002
23/07/02
Bioniche Receives FDA Tentative Approval For Sterile Injectable
17/07/02
Bioniche Receives FDA Approval for EDTA Injection
08/07/02
“Bioniche Animal Health” New Name for Vetrepharm
03/07/02
Bioniche Appoints Martin J. Warmelink New President for Global Animal Health Business
June 2002
14/06/02
Bioniche Hires Dr. Marc Rivière as Senior Vice President and Chief Medical Officer
13/06/02
Bioniche Life Sciences Appoints New Member to its Board
10/06/02
Bioniche Presents Positive Study Findings on Breast Cancer
May 2002
27/05/02
Bioniche Reports Positive 12-Month Results From Bladder Cancer Trial
24/05/02
Bioniche Life Sciences Inc. Receives Ontario Global Traders Award
08/05/02
Bioniche Life Sciences Announces Third Quarter 2002 Results
01/05/02
Bioniche Announces Webcast of Third Quarter 2002 Conference Call
April 2002
19/04/02
Bioniche Subsidiary Receives C$1.8 Million Investment
February 2002
26/02/02
Bioniche Life Sciences signs agreement with US pharmaceutical company
20/02/02
Bioniche Life Sciences Signs Agreement at Team Canada Trade Mission
19/02/02
Bioniche Life Sciences Receives U.S. FDA Approval For Sterile Injectable
06/02/02
Bioniche Life Sciences Reports Strong Second Quarter and First Half 2002 Results
05/02/02
Bioniche Life Sciences Receives U.S. Patent for Company's Lead Technology
04/02/02
Bioniche Life Sciences Strengthens Its Intellectual Property Portfolio With Key U.S. Patent
January 2002
31/01/02
Bioniche Life Sciences Receives Key European Patent For MCC
December 2001
18/12/01
Bioniche Life Sciences Inc. Receives $1.4 Million Funding From Government of Ontario
13/12/01
Bioniche Life Sciences Inc. and Chiesi Sign Suplasyn Distribution Agreement for France
November 2001
01/11/01
Bioniche Life Sciences Inc. Funds $4 Million Research Chair in Food Safety
01/11/01
Bioniche Life Sciences Inc. Acquires Production Facility in Montreal
October 2001
30/10/01
Bioniche Life Sciences Inc. Reports Strong First Quarter Results
05/10/01
Bioniche Life Sciences Inc. Makes Acquisition in Animal Health Sector
05/10/01
Bioniche Life Sciences Inc. Makes Acquisition in Animal Health Sector
September 2001
24/09/01
Bioniche Life Sciences Inc. Announces 2001 Year-End Financial Results
24/09/01
Bioniche Life Sciences Inc. Announces 2001 Year-End Financial Results
July 2001
24/07/01
Bioniche Life Sciences Inc. and Technology Partnerships Canada Hold Ceremony to mark $17.2 Million Investment
24/07/01
Bioniche Life Sciences Inc. and Technology Partnerships Canada Hold Ceremony to mark $17.2 Million Investment
04/07/01
Bioniche Life Sciences Inc. Completes $10 Million Financing
04/07/01
Bioniche Life Sciences Inc. Completes $10 Million Financing
June 2001
28/06/01
Bioniche Life Sciences Inc. Completes First Tranche of $10 Million Financing
25/06/01
Bioniche Reports Phase I/II Bladder Cancer Trial Results
25/06/01
Bioniche Reports Phase I/II Bladder Cancer Trial Results
May 2001
28/05/01
Bioniche Life Sciences Inc. Announces 2001 Third Quarter Financial Results
28/05/01
Bioniche Life Sciences Inc. Announces 2001 Third Quarter Financial Results
28/05/01
Bioniche Life Sciences Inc. Announces 2001 Third Quarter Financial Results
April 2001
19/04/01
Bioniche Life Sciences Marks Progress in Global Expansion
19/04/01
Bioniche Life Sciences Marks Progress in Global Expansion
March 2001
13/03/01
Bioniche Life Sciences Completes Major European Distribution Network with New Partner
13/03/01
Bioniche Life Sciences Completes Major European Distribution Network with New Partner
07/03/01
Bioniche Life Sciences Enters North American Urology Collaboration
February 2001
22/02/01
Bioniche Life Sciences Inc. Announces Second Quarter 2001 Financial Results
January 2001
17/01/01
Bioniche Announces Approval to Begin Phase I Study of MCC as Treatment for Prostate Cancer
December 2000
19/12/00
Bioniche Reports Interim Bladder Cancer Trial Results - An encouraging 57% positive response rate demonstrated -
05/12/00
Bioniche Recognized as one of Canada’s Top-Ten Emerging Biotech Companies
November 2000
28/11/00
Bioniche Life Sciences Inc. Announces 2001 First Quarter Financial Results
16/11/00
Bioniche Life Sciences Provides Preclinical Scientific Update
October 2000
30/10/00
Bioniche Life Sciences Announces New Distribution Agreements for Suplasyn
September 2000
28/09/00
Bioniche Life Sciences' Cystistat® Gets Marketing Boost in Germany
20/09/00
New E.coli vaccine to be produced in Canada
19/09/00
Bioniche Life Sciences Inc. Announces Year-end Results
13/09/00
Bioniche Presents Important New Anti-Cancer Findings at the Hyaluronan 2000 International Meeting
07/09/00
Bioniche Receives Approval for Expanded Indications in Europe for Cystistat®
August 2000
31/08/00
Bioniche Presents Leukemia Study Findings at 28th World Congress of The International Society Of Hematology
14/08/00
Bioniche’s MCC Shows Broad Activity Against Prostate Cancer in Preclinical Testing
June 2000
28/06/00
Bioniche Life Sciences Inc. announces Italian distribution agreement for Cystistat®
07/06/00
Bioniche Life Sciences Inc. Discovers New Class of Molecules with Potent Anti-Cancer Activity
05/06/00
Bioniche Life Sciences Inc.'s Animal Health Subsidiary Divests Autogenous Bacterin Division - Divestiture Allows Vetrepharm to Focus on Major Pipeline Products
May 2000
10/05/00
Marketing opportunities expand for Bioniche Life Sciences' Cystistat® - Company Receives Approval for Expanded Indications in Canada
February 2000
02/02/00
Bioniche Life Sciences Inc. announces completion of $13 million financing
January 2000
27/01/00
Bioniche Life Sciences Inc. announces licensing agreement with Merckle for German market
10/01/00
Bioniche Life Sciences Inc. announces financing in pharma division
November 1999
29/11/99
Bioniche Life Sciences Inc. announces first quarter results
15/11/99
Bioniche Life Sciences Inc. Announces Year-End Results for Bioniche Inc.
August 1999
19/08/99
Bioniche Announces IND Approval
|
